SLNO Strangle Strategy
SLNO (Soleno Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
SLNO (Soleno Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $2.76B, a trailing P/E of 28.72, a beta of -2.22 versus the broader market, a 52-week range of 29.43-90.32, average daily share volume of 3.5M, a public-listing history dating back to 2014, approximately 115 full-time employees. These structural characteristics shape how SLNO stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of -2.22 indicates SLNO has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a strangle on SLNO?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current SLNO snapshot
As of May 15, 2026, spot at $53.00, ATM IV 14.30%, IV rank 8.81%, expected move 4.10%. The strangle on SLNO below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on SLNO specifically: SLNO IV at 14.30% is on the cheap side of its 1-year range, which favors premium-buying structures like a SLNO strangle, with a market-implied 1-standard-deviation move of approximately 4.10% (roughly $2.17 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated SLNO expiries trade a higher absolute premium for lower per-day decay. Position sizing on SLNO should anchor to the underlying notional of $53.00 per share and to the trader's directional view on SLNO stock.
SLNO strangle setup
The SLNO strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With SLNO near $53.00, the first option leg uses a $55.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed SLNO chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 SLNO shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $55.00 | $0.30 |
| Buy 1 | Put | $50.00 | $0.11 |
SLNO strangle risk and reward
- Net Premium / Debit
- -$41.00
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- -$41.00
- Breakeven(s)
- $49.60, $55.41
- Risk / Reward Ratio
- Unbounded
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
SLNO strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on SLNO. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | +$4,958.00 |
| $11.73 | -77.9% | +$3,786.25 |
| $23.44 | -55.8% | +$2,614.50 |
| $35.16 | -33.7% | +$1,442.75 |
| $46.88 | -11.5% | +$271.01 |
| $58.60 | +10.6% | +$318.74 |
| $70.31 | +32.7% | +$1,490.49 |
| $82.03 | +54.8% | +$2,662.24 |
| $93.75 | +76.9% | +$3,833.99 |
| $105.47 | +99.0% | +$5,005.74 |
When traders use strangle on SLNO
Strangles on SLNO are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the SLNO chain.
SLNO thesis for this strangle
The market-implied 1-standard-deviation range for SLNO extends from approximately $50.83 on the downside to $55.17 on the upside. A SLNO long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current SLNO IV rank near 8.81% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on SLNO at 14.30%. As a Healthcare name, SLNO options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to SLNO-specific events.
SLNO strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. SLNO positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move SLNO alongside the broader basket even when SLNO-specific fundamentals are unchanged. Always rebuild the position from current SLNO chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on SLNO?
- A strangle on SLNO is the strangle strategy applied to SLNO (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With SLNO stock trading near $53.00, the strikes shown on this page are snapped to the nearest listed SLNO chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are SLNO strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the SLNO strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 14.30%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$41.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a SLNO strangle?
- The breakeven for the SLNO strangle priced on this page is roughly $49.60 and $55.41 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current SLNO market-implied 1-standard-deviation expected move is approximately 4.10%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on SLNO?
- Strangles on SLNO are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the SLNO chain.
- How does current SLNO implied volatility affect this strangle?
- SLNO ATM IV is at 14.30% with IV rank near 8.81%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.